Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties.

Article Details

Citation
Copy to clipboard

Staniforth DH, Pennick M

Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties.

Eur J Clin Pharmacol. 1990;38(2):161-4.

PubMed ID
2338113 [ View in PubMed
]
Abstract

The activity of the substituted benzamide renzapride on the upper gastrointestinal tract has been investigated. It has been shown to enhance stomach emptying in normal subjects; doses of 2 and 5 mg decreasing by 21 and 37% respectively the volume of gastric contents aspirated 80 min after a test meal. Renzapride was found to reduce the oro-caecal transit time as assessed by the lactulose/breath hydrogen method in a dose related manner from 0.2 to 5 mg; the later dose producing a 62% reduction. Finally renzapride was shown not to elevate plasma prolactin at a dose of 5 mg, a finding consistent with lack of dopamine receptor antagonism.

DrugBank Data that Cites this Article

Drugs